Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Exploring the Safety and Efficacy of Renal Denervation in Electrical Storm Management
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 04 - INOVAÇÃO EM CUIDADOS INTENSIVOS: NOVAS INTERVENÇÕES EM CHOQUE CARDIOGÉNICO E SÍNDROMAS CORONÁRIAS AGUDAS
Speaker:
Mariana Caetano Coelho
Congress:
CPC 2025
Topic:
C. Arrhythmias and Device Therapy
Theme:
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
Subtheme:
08.4 Ventricular Arrhythmias and SCD - Treatment
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Mariana Caetano Coelho; Sofia Jacinto; Ana Rita Teixeira; Inês Ferreira Neves; Guilherme Portugal; Bruno Valente; Ana Lousinha; Pedro Silva Cunha; Hélder Santos; Paulo Osório; Rui Cruz Ferreira; Mário Martins Oliveira
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Catheter ablation (CA) has shown efficacy in managing ventricular arrhythmias (VA) associated with structural heart disease. However, some patients continue to experience refractory VA despite pharmacological therapy and multiple CA attempts. In such cases, additional interventions, including autonomic neuromodulation, have been investigated. Renal denervation (RDN), a technique originally developed to treat resistant arterial hypertension, works by inhibiting the afferent renal sympathetic pathways, thereby reducing systemic sympathetic overactivity. Given this mechanism, RDN has been studied as a therapeutic option for arrhythmias, including atrial fibrillation and VA, with promising outcomes.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">This study aims to evaluate both the effectiveness and safety profile of renal denervation as a therapeutic strategy for managing refractory ventricular arrhythmia storms in patients classified as high-risk.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">A retrospective analysis was conducted on renal denervation procedures performed to manage electrical storms at a tertiary center from February 2020 to October 2024. Baseline patient characteristics, procedural details, and acute complications were recorded. Recurrence of ventricular arrhythmia post-RDN was evaluated at one month and six months to assess the intervention's impact on arrhythmia control.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">A total of 11 patients underwent RDN for the treatment of refractory VA. The cohort had a mean age of 63 ± 10 years, with 9 males. The primary diagnosis in most patients was ischemic cardiomyopathy (n=7), characterized by a mean left ventricular ejection fraction of 25 ± 8%. All patients had implantable cardioverter-defibrillators (ICDs), and two of these devices included concomitant cardiac resynchronization therapy. Nine patients had previously undergone endocardial VA ablation. Among the two patients without prior ablation, one was contraindicated due to a large left ventricular thrombus, while the other underwent an electrophysiological study without inducible ventricular tachycardia. In the four weeks preceding RDN, patients experienced an average of 18 ± 20 sustained VA episodes, meeting the criteria for an electrical storm (≥3 episodes within 24 hours). During RDN, a mean of 15 ± 9 radiofrequency applications were delivered to the right renal artery and 12 ± 9 to the left renal artery. No acute procedural complications were observed. One month post-RDN, VA episodes were reduced to a mean of 0 ± 1, with only two patients experiencing recurrent VA. At the six-month follow-up, VA recurrence remained low (mean 1 ± 2 episodes), and at one year, there was an increase in mean episodes (29 ± 50), with only one patient experiencing new episodes. There were four deaths during the follow-up period, three of which were attributable to heart failure.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif">Conclusion: In our pilot study, RDN appeared to be a safe and effective treatment for the management of VA.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site